Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
Belanoff et al. • 2010 • Diabetes Obes Metab. 2010;12(6):545-7.
© 2024 Corcept Therapeutics, Incorporated
Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis
Elhassan et al • 2019 • Ann Intern Med.
Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective Glucocorticoid Receptor (GR) antagonist.
Hunt et al. • 2017 • J Med Chem. 2017;60(8):3405-3421.
1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoidreceptor antagonists with high functional activity.
Clark et al. • 2008 • Bioorg Med Chem Lett. 2008;18(4):1312-7.
Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.
Hunt et al. • 2017 • Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.
FKBP5 mRNA expression is a biomarker for GR antagonism.
Bali et al. • 2016 • J Clin Endocrinol Metab. 2016;101(11):4305-4312.
A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain.
Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.
Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.
Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.
Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.
Hunt et al. • 2012 • Bioorg Med Chem Lett. 2012;22(24):7376-80.
Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice.
Asagami et al. • 2011 • J Nutr Metab. 2011;2011:235389.